Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-03-24 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
EVUSHELD POSITIVE EU CHMP OPINION
Foreign Filer Report
2022-03-24 English
Evusheld Positive EU CHMP Opinion
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9754F' and is dated '24 March 2022'. It contains a headline about a regulatory recommendation ('Evusheld long-acting antibody combination recommended for approval in the EU') and details a positive opinion from the CHMP of the European Medicines Agency. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which fits the definition of Regulatory Filings (RNS), as it is an announcement of a regulatory event rather than a comprehensive financial report (like 10-K or IR) or a specific management/dividend notice.
2022-03-24 English
UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA
Foreign Filer Report
2022-03-24 English
Update on CALLA Phase III trial for Imfinzi
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8857F' and is dated March 24, 2022. It announces the results of a Phase III clinical trial (CALLA) for the drug Imfinzi, stating that the primary endpoint was not met. This is a specific, material announcement regarding clinical development and results, which is typically disseminated via regulatory news services. Since it is a specific announcement of clinical trial results rather than a full financial report (10-K, IR) or a general earnings release (ER), it fits best under the general regulatory announcement category, RNS, as it is explicitly sourced from RNS and contains information that is not covered by other specific codes like ER, AR, or CT. Given the content is a specific update on a clinical trial, it is a regulatory disclosure, and RNS is the appropriate fallback/general regulatory category when a more specific code (like a specific FDA filing type not listed) is unavailable.
2022-03-24 English
NOTICE OF AGM
Foreign Filer Report
2022-03-23 English
FORM 6-K
Foreign Filer Report
2022-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.